Charles Explorer logo
🇬🇧

Treatment decisions in chronic myeloid leukemia in the view of BCR-ABL1 mutations in practice

Publication at Faculty of Medicine in Hradec Králové |
2010

Abstract

Decisions in tailored treatment of chronic myeloid leukemia with second generation tyrosine kinase inhibitors and the use of BCR-ABL1 mutations results are demonstrated via casuistic.